Teva Pharmaceutical Industries Ltd. (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: September 13, 2016
Pages: 281
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T3E12D7D2CAEN
Leaflet:

Download PDF Leaflet

Teva Pharmaceutical Industries Ltd. (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Teva Pharmaceutical Industries Ltd. (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generics, branded pharmaceuticals and active pharmaceutical ingredients (APIs). It offers chemical and generic medicines in various forms such as capsules, tablets, ointments, liquids, creams, injectables and inhalants. The company offers specialty pharmaceuticals in central nervous system, respiratory, cancer and women’s health. Teva also provides over-the-counter (OTC) products through a joint venture with P&G in Israel and Hungary. It has operations in United States, Europe and Rest of the World (Japan, Canada, Venezuela and Russia). Teva is headquartered in Tikva, Israel.

Teva Pharmaceutical Industries Ltd. (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Medical Devices Deals, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Teva Pharma Acquires Generics Drug Business from Allergan for USD38.8 Billion
Unichem Labs May Sell its Domestic Formulations Business
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million
Teva Plans To Acquire Three Women's Health Divisions
Venture Financing
Auspex Pharma Raises US$20 Million In Series E Financing
Labrys Biologics Raises US$31 Million In Series A Financing
Auspex Pharma Raises US$25 Million In Series D Financing
Auspex Pharma Raises US$1.5 Million In Venture Financing
Gamida Cell Raises US$10 Million In Series E Financing
Teva Pharma Industries Invests In MultiGene Vascular Systems
VBL Biogenics Secures US$40 Million In Venture Financing
Auspex Pharma Raises US$12 Million In Series C Financing
Auspex Pharma Raises US$2 Million In Venture Financing
Partnerships
Alexza Pharma Terminates Licensing Agreement with Teva Pharma for Adasuve Inhalation Powder
Teva Pharma Industries Amends Licensing Agreement With Active Biotech
Teva Pharma and Takeda Pharma Form Joint Venture
Teva Pharma Enters into Research Agreement with AbCellera Biologics
Egalet Enters into Agreement with Teva Pharma
Teva Pharma Partners with University College London and Imanova
Teva Pharma Enters into an Agreement with Microchips Biotech
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs
Champions Enters Into Drug Discovery And Development Agreement With Teva
Teva Pharma Plans To Enter Into Partnerships
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
Teva Pharma And Lonza Terminate Joint Venture For Biosimilars
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test
Teva Pharma Terminates Co-Development Agreement With CureTech For CT-011
Teva Pharma To Form Joint Venture With Handok Pharma
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Teva Pharma And Proctor & Gamble Finalize Joint Venture
Teva Pharma Forms Joint Venture With Procter & Gamble
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra
Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries
Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries
UCB Terminates Co-Marketing Agreement With Teva Pharma
Licensing Agreements
Checkpoint Therapeutics Enters into Licensing Agreement with Teva Pharma
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics
Teva Pharma Terminates Licensing Agreement with Oncogenex Pharma for OGX-011
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102
Cell Cure Neurosciences Terminates Licensing Option Agreement with Teva Pharma Industries for OpRegen
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma
Andromeda Terminates Licensing Agreement With Teva Pharma For DiaPep277 Rights
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307
Teva Pharma Terminates Licensing Agreement With Proteologics
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402
Teva Pharma Terminates Licensing Agreement With MediWound For NexoBrid
Hospira Terminates Licensing Agreement With Ivax International For Omacetaxine Mepesuccinate
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC
Watson Pharma Enters Into Licensing Agreement With Teva Pharma
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Barr Labs
Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva
Antisense Therapeutics Terminates Licensing Agreement With Teva Pharma
MediGene Enters Into Licensing Agreement With Teva Pharma
Equity Offering
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares
American Well Raises USD10 Million in Private Placement of Shares
Ignyta Raises USD42 Million in Private Placement of Shares
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares
Auspex Pharma Completes IPO For US$96.6 Million
Debt Offering
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$250 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$500 Million
ChemGenex Completes Private Placement Of Convertible Notes For US$15 Million
Teva Pharma Completes Private Placement Of 1.5% Senior Notes For US$1,000 Million
Teva Pharma Completes Private Placement Of Senior Notes For US$500 Million
Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For US$1,000 Million
Asset Transactions
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma
Aurobindo Pharma and Intas Pharma May Acquire Certain Products of Teva Pharma in Europe for USD1 Billion
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire
Impax Labs to Acquire Generic Products from Teva Pharma and Allergan for USD586 Million
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma
Teva Pharma May Divest its Assets
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma
Teva Pharma Plans to Divest Some Operations
ANI Pharma Acquires ANDA from Teva Pharma
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California
CleveXel Pharma Acquires Development Center From Teva Pharma
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
Perrigo Acquires Rights For Allegra From Teva Pharma
Acquisition
Teva Pharma to Acquire Anda from Allergan for USD500 Million
Teva Pharma, Mylan May Acquire Teut|Pfizer
Teva Pharma Acquires Rimsa for USD2.3 Billion
Teva Pharma to Acquire Gecko Health Innovations
Teva Pharma to Acquire 51% Stake in Immuneering
Teva Pharma Terminates Acquisition of Mylan
Teva Pharma Acquires Auspex Pharma
Ind-Swift Lab May Sell Stake in Company
Teva Pharma Completes Acquisition of Labrys Biologics
Novartis Terminates Planned Acquisition Of Gamida Cell For US$600 Million
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer
Teva Pharma Completes Acquisition of MicroDose Therapeutx
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million
Teva Pharma Rumored To Acquire Amarin
Teva Completes Acquisition Of Cephalon For US$6,800 Million
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million
Teva Pharma Invests Additional US$19 Million In CureTech
Teva Pharma Industries Acquires Taiyo Pharma Industry
Cephalon Acquires 91.73% Stake In ChemGenex
Clal Biotech Acquires Stake In TransPharma Medical From Teva
Teva Pharma Industries Acquires Corporacion Infarmasa
Teva Pharma Industries Acquires THERAMEX From Merck Serono
Teva Pharma Industries Completes Acquisition Of ratiopharm For Approximately US$4.9 Billion
Teva Pharmaceutical Industries Ltd. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Key Facts, 2015
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Deals By Therapy Area, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Medical Devices Deals, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016
Teva Pharma Acquires Generics Drug Business from Allergan for USD38.8 Billion
Unichem Labs May Sell its Domestic Formulations Business
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million
Teva Plans To Acquire Three Women's Health Divisions
Auspex Pharma Raises US$20 Million In Series E Financing
Labrys Biologics Raises US$31 Million In Series A Financing
Auspex Pharma Raises US$25 Million In Series D Financing
Auspex Pharma Raises US$1.5 Million In Venture Financing
Gamida Cell Raises US$10 Million In Series E Financing
Teva Pharma Industries Invests In MultiGene Vascular Systems
VBL Biogenics Secures US$40 Million In Venture Financing
Auspex Pharma Raises US$12 Million In Series C Financing
Auspex Pharma Raises US$2 Million In Venture Financing
Alexza Pharma Terminates Licensing Agreement with Teva Pharma for Adasuve Inhalation Powder
Teva Pharma Industries Amends Licensing Agreement With Active Biotech
Teva Pharma and Takeda Pharma Form Joint Venture
Teva Pharma Enters into Research Agreement with AbCellera Biologics
Egalet Enters into Agreement with Teva Pharma
Teva Pharma Partners with University College London and Imanova
Teva Pharma Enters into an Agreement with Microchips Biotech
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs
Champions Enters Into Drug Discovery And Development Agreement With Teva
Teva Pharma Plans To Enter Into Partnerships
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
Teva Pharma And Lonza Terminate Joint Venture For Biosimilars
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test
Teva Pharma Terminates Co-Development Agreement With CureTech For CT-011
Teva Pharma To Form Joint Venture With Handok Pharma
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Teva Pharma And Proctor & Gamble Finalize Joint Venture
Teva Pharma Forms Joint Venture With Procter & Gamble
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra
Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries
Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries
UCB Terminates Co-Marketing Agreement With Teva Pharma
Checkpoint Therapeutics Enters into Licensing Agreement with Teva Pharma
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics
Teva Pharma Terminates Licensing Agreement with Oncogenex Pharma for OGX-011
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102
Cell Cure Neurosciences Terminates Licensing Option Agreement with Teva Pharma Industries for OpRegen
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma
Andromeda Terminates Licensing Agreement With Teva Pharma For DiaPep277 Rights
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307
Teva Pharma Terminates Licensing Agreement With Proteologics
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402
Teva Pharma Terminates Licensing Agreement With MediWound For NexoBrid
Hospira Terminates Licensing Agreement With Ivax International For Omacetaxine Mepesuccinate
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC
Watson Pharma Enters Into Licensing Agreement With Teva Pharma
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Barr Labs
Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva
Antisense Therapeutics Terminates Licensing Agreement With Teva Pharma
MediGene Enters Into Licensing Agreement With Teva Pharma
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares
American Well Raises USD10 Million in Private Placement of Shares
Ignyta Raises USD42 Million in Private Placement of Shares
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares
Auspex Pharma Completes IPO For US$96.6 Million
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$250 Million
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$500 Million
ChemGenex Completes Private Placement Of Convertible Notes For US$15 Million
Teva Pharma Completes Private Placement Of 1.5% Senior Notes For US$1,000 Million
Teva Pharma Completes Private Placement Of Senior Notes For US$500 Million
Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For US$1,000 Million
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma
Aurobindo Pharma and Intas Pharma May Acquire Certain Products of Teva Pharma in Europe for USD1 Billion
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire
Impax Labs to Acquire Generic Products from Teva Pharma and Allergan for USD586 Million
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma
Teva Pharma May Divest its Assets
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma
Teva Pharma Plans to Divest Some Operations
ANI Pharma Acquires ANDA from Teva Pharma
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California
CleveXel Pharma Acquires Development Center From Teva Pharma
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
Perrigo Acquires Rights For Allegra From Teva Pharma
Teva Pharma to Acquire Anda from Allergan for USD500 Million
Teva Pharma, Mylan May Acquire Teut|Pfizer
Teva Pharma Acquires Rimsa for USD2.3 Billion
Teva Pharma to Acquire Gecko Health Innovations
Teva Pharma to Acquire 51% Stake in Immuneering
Teva Pharma Terminates Acquisition of Mylan
Teva Pharma Acquires Auspex Pharma
Ind-Swift Lab May Sell Stake in Company
Teva Pharma Completes Acquisition of Labrys Biologics
Novartis Terminates Planned Acquisition Of Gamida Cell For US$600 Million
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer
Teva Pharma Completes Acquisition of MicroDose Therapeutx
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million
Teva Pharma Rumored To Acquire Amarin
Teva Completes Acquisition Of Cephalon For US$6,800 Million
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million
Teva Pharma Invests Additional US$19 Million In CureTech
Teva Pharma Industries Acquires Taiyo Pharma Industry
Cephalon Acquires 91.73% Stake In ChemGenex
Clal Biotech Acquires Stake In TransPharma Medical From Teva
Teva Pharma Industries Acquires Corporacion Infarmasa
Teva Pharma Industries Acquires THERAMEX From Merck Serono
Teva Pharma Industries Completes Acquisition Of ratiopharm For Approximately US$4.9 Billion
Teva Pharmaceutical Industries Ltd., Key Competitors
Teva Pharmaceutical Industries Ltd., Key Employees
Teva Pharmaceutical Industries Ltd., Subsidiaries

LIST OF FIGURES

Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
Teva Pharmaceutical Industries Ltd., Medical Devices Deals, 2010 to YTD 2016
Skip to top


Ask Your Question

Teva Pharmaceutical Industries Ltd. (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: